Tags

Type your tag names separated by a space and hit enter

Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.

Abstract

The diagnosis of AD is still largely based on exclusion criteria of secondary causes and other forms of dementia with similar clinical pictures, than the diagnostic accuracy of AD is low. Improved methods of early diagnosis are needed, particularly because drugs treatment is more effective in the early stages of the disease. Recent research focused the attention to biochemical diagnostic markers (biomarkers) and according to the proposal of a consensus group on biomarkers, three candidate CSF markers reflecting the pathological AD processes, have recently been identified: total tau protein (t-tau), amyloid beta(1-42) protein (A beta42), and tau protein phosphorylated at AD-specific epitopes (p-tau). Several articles report reduced CSF levels of A beta42 and increased CSF levels of t-tau and p-tau in AD; the sensitivity and specificity of these data are able for discrimination of AD patients from controls. However, the specificity for other dementias is low. According to the literature analysis reported in the present review, we can conclude that the combination of the CSF markers and their ratios may significantly increase the specificity and the accuracy of AD diagnosis.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Neurological and Behavioural Sciences, University of Siena, Siena, Italy.

    , ,

    Source

    Journal of cellular physiology 208:1 2006 Jul pg 39-46

    MeSH

    Alzheimer Disease
    Amyloid beta-Peptides
    Biomarkers
    Cognition Disorders
    Dementia
    Early Diagnosis
    Enzyme-Linked Immunosorbent Assay
    Epitopes
    Humans
    Nerve Degeneration
    Nerve Tissue Proteins
    Oxidative Stress
    Peptide Fragments
    Phosphorylation
    Protein Kinases
    Sensitivity and Specificity
    tau Proteins

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't
    Review

    Language

    eng

    PubMed ID

    16447254

    Citation

    Formichi, Patrizia, et al. "Cerebrospinal Fluid Tau, a Beta, and Phosphorylated Tau Protein for the Diagnosis of Alzheimer's Disease." Journal of Cellular Physiology, vol. 208, no. 1, 2006, pp. 39-46.
    Formichi P, Battisti C, Radi E, et al. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. J Cell Physiol. 2006;208(1):39-46.
    Formichi, P., Battisti, C., Radi, E., & Federico, A. (2006). Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. Journal of Cellular Physiology, 208(1), pp. 39-46.
    Formichi P, et al. Cerebrospinal Fluid Tau, a Beta, and Phosphorylated Tau Protein for the Diagnosis of Alzheimer's Disease. J Cell Physiol. 2006;208(1):39-46. PubMed PMID: 16447254.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. AU - Formichi,Patrizia, AU - Battisti,Carla, AU - Radi,Elena, AU - Federico,Antonio, PY - 2006/2/1/pubmed PY - 2006/7/27/medline PY - 2006/2/1/entrez SP - 39 EP - 46 JF - Journal of cellular physiology JO - J. Cell. Physiol. VL - 208 IS - 1 N2 - The diagnosis of AD is still largely based on exclusion criteria of secondary causes and other forms of dementia with similar clinical pictures, than the diagnostic accuracy of AD is low. Improved methods of early diagnosis are needed, particularly because drugs treatment is more effective in the early stages of the disease. Recent research focused the attention to biochemical diagnostic markers (biomarkers) and according to the proposal of a consensus group on biomarkers, three candidate CSF markers reflecting the pathological AD processes, have recently been identified: total tau protein (t-tau), amyloid beta(1-42) protein (A beta42), and tau protein phosphorylated at AD-specific epitopes (p-tau). Several articles report reduced CSF levels of A beta42 and increased CSF levels of t-tau and p-tau in AD; the sensitivity and specificity of these data are able for discrimination of AD patients from controls. However, the specificity for other dementias is low. According to the literature analysis reported in the present review, we can conclude that the combination of the CSF markers and their ratios may significantly increase the specificity and the accuracy of AD diagnosis. SN - 0021-9541 UR - https://www.unboundmedicine.com/medline/citation/16447254/Cerebrospinal_fluid_tau_A_beta_and_phosphorylated_tau_protein_for_the_diagnosis_of_Alzheimer's_disease_ L2 - https://doi.org/10.1002/jcp.20602 DB - PRIME DP - Unbound Medicine ER -